Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ZYRTEC HIVES RELIEF versus CLARINEX D 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ZYRTEC HIVES RELIEF versus CLARINEX D 12 HOUR.
CHILDREN'S ZYRTEC HIVES RELIEF vs CLARINEX-D 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. It also inhibits eosinophil chemotaxis and mast cell mediator release.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
For adults, the recommended dose of cetirizine (active ingredient in Children's Zyrtec Hives Relief) is 10 mg orally once daily. Route: oral. Frequency: once daily.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 8-11 hours in healthy adults, allowing once-daily dosing. In renal impairment (CrCl <30 mL/min), half-life may increase to 20-30 hours requiring dose adjustment.
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
Renal excretion accounts for approximately 70% of the administered dose, primarily as unchanged drug via tubular secretion. Fecal elimination is about 10% with the remainder metabolized.
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination